½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1588942

¼¼°èÀÇ ºñ¼Ò¼¼Æ÷Æó¾Ï(NSCLC) Ä¡·áÁ¦ ½ÃÀå

Non-Small Cell Lung Cancer (NSCLC) Therapeutics

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Industry Analysts, Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 89 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ºñ¼Ò¼¼Æ÷Æó¾Ï(NSCLC) Ä¡·áÁ¦ ¼¼°è ½ÃÀå, 2030³â±îÁö 540¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î Àü¸Á

2023³â 304¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ºñ¼Ò¼¼Æ÷Æó¾Ï(NSCLC) Ä¡·áÁ¦ ¼¼°è ½ÃÀåÀº 2023-2030³â µ¿¾È ¿¬Æò±Õ 8.5% ¼ºÀåÇÏ¿© 2030³â¿¡´Â 540¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀΠǥÀûÄ¡·áÁ¦´Â CAGR 9.6%¸¦ ±â·ÏÇÏ¿© ºÐ¼® ±â°£ Á¾·á ½ÃÁ¡¿¡ 313¾ï ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¸é¿ª¿ä¹ý ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 7.5%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀå 79¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 12.9%·Î ¼ºÀå Àü¸Á

¹Ì±¹ÀÇ ºñ¼Ò¼¼Æ÷Æó¾Ï(NSCLC) Ä¡·áÁ¦ ½ÃÀåÀº 2023³â 79¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 141¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2023-2030³â ºÐ¼® ±â°£ µ¿¾È 12.9%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ª ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ µ¿¾È °¢°¢ 4.2%¿Í 7.5%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ ¿¬Æò±Õ 5.1%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è ºñ¼Ò¼¼Æ÷Æó¾Ï(NSCLC) Ä¡·áÁ¦ ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ ¿ä¾à

¾Ï ¿µ¿ª¿¡¼­ ºñ¼Ò¼¼Æ÷Æó¾Ï(NSCLC) Ä¡·áÁ¦°¡ Áß¿äÇÑ ÀÌÀ¯

ºñ¼Ò¼¼Æ÷Æó¾Ï(NSCLC)Àº °¡Àå ÈçÇÑ Æó¾ÏÀÇ ÀÏÁ¾À¸·Î Àü ¼¼°è Æó¾Ï ȯÀÚÀÇ ¾à 85%¸¦ Â÷ÁöÇϸç, ºñ¼Ò¼¼Æ÷Æó¾Ï Ä¡·áÁ¦´Â ƯÁ¤ À¯ÀüÀÚ º¯À̸¦ Ç¥ÀûÀ¸·Î »ï¾Æ ȯÀÚÀÇ »ýÁ¸À²À» ³ôÀÌ°í ±âÁ¸ È­Çпä¹ýÀÇ ºÎÀÛ¿ëÀ» ÁÙÀ̱â À§ÇØ °í¾ÈµÇ¾ú½À´Ï´Ù. Ä¡·á¹ý¿¡´Â ¼ö¼ú, ¹æ»ç¼± ¿ä¹ý, È­Çпä¹ý, Ç¥Àû ¿ä¹ý, ¸é¿ª¿ä¹ý µîÀÌ ÀÖÀ¸¸ç, ÈÄÀÚÀÇ µÎ °¡Áö Ä¡·á¹ýÀº ÁøÇ༺ ºñ¼Ò¼¼Æ÷Æó¾ÏÀÇ ¿¹Èĸ¦ °³¼±ÇÒ ¼ö ÀÖ´Â Å« ÀáÀç·ÂÀ» º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î Æó¾ÏÀÇ ºÎ´ãÀÌ °è¼Ó Áõ°¡ÇÔ¿¡ µû¶ó, ºñ¼Ò¼¼Æ÷Æó¾Ï Ä¡·áÁ¦´Â Á¾¾çÇаèÀÇ ÃÊÁ¡ÀÌ µÇ°í ÀÖÀ¸¸ç, ȯÀڵ鿡°Ô º¸´Ù °³ÀÎÈ­µÈ Ä¡·á ¿É¼ÇÀ» Á¦°øÇÏ°í ÀÖ½À´Ï´Ù.

NSCLC Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ºÎ¹®Àº?

ÁÖ¿ä Ä¡·á À¯Çü¿¡´Â È­Çпä¹ý, Ç¥ÀûÄ¡·áÁ¦, ¸é¿ª¿ä¹ý, º´¿ë¿ä¹ý µîÀÌ ÀÖÀ¸¸ç, Ç¥ÀûÄ¡·áÁ¦¿Í ¸é¿ª¿ä¹ýÀº ºñ¼Ò¼¼Æ÷Æó¾ÏÀÇ Æ¯Á¤ À¯ÀüÀÚ ¾ÆÇü¿¡ È¿°úÀûÀ̱⠶§¹®¿¡ ºü¸£°Ô ¼ºÀåÇÏ°í ÀÖ½À´Ï´Ù. EGFR ¾ïÁ¦Á¦, ALK ¾ïÁ¦Á¦, PD-1/PD-L1 ¾ïÁ¦Á¦, VEGF ¾ïÁ¦Á¦ µî EGFR µ¹¿¬º¯ÀÌ ¹× ALK µ¹¿¬º¯À̸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â µ¹¿¬º¯ÀÌ Æ¯ÀÌÀû Ä¡·áÁ¦´Â ȯÀÚÀÇ ¹«ÁøÇà»ýÁ¸±â°£À» ¿¬Àå½ÃÅ°´Â µ¥ ƯÈ÷ ¼º°øÀûÀ̾ú½À´Ï´Ù. ÁÖ¿ä ÃÖÁ¾»ç¿ëÀڷδ º´¿ø, ¾Ï Ä¡·á ¼¾ÅÍ, ¿¬±¸±â°ü µîÀÌ ÀÖÀ¸¸ç, ÀÌµé ¸ðµÎ ºñ¼Ò¼¼Æ÷Æó¾Ï °ü¸® ÇÁ·ÎÅäÄÝ¿¡ ÀÌ·¯ÇÑ Ã·´Ü Ä¡·á¹ýÀ» ÅëÇÕÇÏ°í ÀÖ½À´Ï´Ù.

NSCLC Ä¡·áÁ¦´Â ¾î¶»°Ô ¾Ï Ä¡·á¸¦ º¯È­½ÃÅ°°í Àִ°¡?

º´¿ø°ú Á¾¾ç¼¾ÅÍ´Â À¯ÀüÀÚ °Ë»ç ¹× ¹ÙÀÌ¿À¸¶Ä¿ ºÐ¼®À» ÅëÇØ ºñ¼Ò¼¼Æ÷Æó¾Ï Ä¡·áÁ¦¸¦ °³º°È­µÈ Ä¡·á °èȹ¿¡ ÅëÇÕÇÏ°í ÀÖÀ¸¸ç, EGFR ¾ïÁ¦Á¦ ¹× ALK ¾ïÁ¦Á¦¿Í °°Àº Ç¥Àû Ä¡·áÁ¦´Â ƯÁ¤ µ¹¿¬º¯À̸¦ °¡Áø ȯÀÚ¿¡°Ô ó¹æµÇ´Â °æ¿ì°¡ ¸¹À¸¸ç, ±âÁ¸ È­Çпä¹ý¿¡ ºñÇØ ºÎÀÛ¿ëÀÌ Àû°í ´õ È¿°úÀûÀÎ Ä¡·á¹ýÀ» Á¦°øÇÕ´Ï´Ù. PD-1/PD-L1 ¾ïÁ¦Á¦¿Í °°Àº ¸é¿ª¿ä¹ýÀº 1Â÷ ¹× 2Â÷ Ä¡·áÁ¦·Î »ç¿ëµÇ¾î ÁøÇ༺ ºñ¼Ò¼¼Æ÷Æó¾Ï ȯÀÚÀÇ »ýÁ¸À²À» Çâ»ó½ÃÅ°°í ÀÖ½À´Ï´Ù. ¿¬±¸±â°ü°ú Á¦¾à»çµéÀº ºñ¼Ò¼¼Æ÷Æó¾Ï¿¡ ´ëÇÑ È¿°úÀûÀÎ Ä¡·á¹ýÀÇ ÆøÀ» ³ÐÈ÷±â À§ÇØ Àû±ØÀûÀ¸·Î ½Å¾àÀ» °³¹ßÇÏ°í ÀÓ»ó½ÃÇèÀ» ÁøÇàÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ç¥ÀûÄ¡·áÁ¦¿Í ¸é¿ª¿ä¹ýÀ» ÅëÇÕÇÑ º´¿ë¿ä¹ýÀº ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÏ°í ´Üµ¶¿ä¹ý¿¡ ´ëÇÑ ³»¼ºÀ» °ü¸®ÇÏ´Â µ¥ ÀÖ¾î À¯¸ÁÇÑ °á°ú¸¦ º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù.

NSCLC Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

NSCLC Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀº Æó¾Ï À¯º´·ü Áõ°¡, È¿°úÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. À¯ÀüüÇÐ ¹× ¸ÂÃãÀÇ·áÀÇ ¹ßÀüÀ¸·Î Ç¥ÀûÄ¡·áÁ¦ °³¹ßÀÌ °¡¼ÓÈ­µÇ¾î ƯÁ¤ ºñ¼Ò¼¼Æ÷Æó¾Ï ¾ÆÇü¿¡ ´ëÇÑ º¸´Ù Á¤¹ÐÇÑ Ä¡·á°¡ °¡´ÉÇØÁ³½À´Ï´Ù. »ýÁ¸À² °³¼±¿¡ ÀÖ¾î ¸é¿ªÄ¡·áÀÇ ¼º°øÀº Çõ½ÅÀûÀÎ ºñ¼Ò¼¼Æ÷Æó¾Ï Ä¡·áÁ¦ÀÇ Ã¤ÅÃÀ» ´õ¿í ÃËÁøÇÏ°í ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀΰú ¿¬±¸ À̴ϼÅƼºêÀÇ È®´ëµµ »õ·Î¿î Ä¡·áÁ¦ÀÇ ½ÃÀå ÁøÀÔÀ» ÃËÁøÇÏ°í ÀÖ½À´Ï´Ù. À¯ÀüÀÚ °Ë»ç ¹× ¹ÙÀÌ¿À¸¶Ä¿ ½Äº°¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ Ç¥ÀûÄ¡·áÁ¦ äÅÃÀ» ÃËÁøÇÏ°í ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾Ï ¿¬±¸¿¡ ´ëÇÑ Á¤ºÎÀÇ ÀÚ±Ý Áö¿ø°ú ÅõÀÚ°¡ »õ·Î¿î Ä¡·á¹ý °³¹ßÀ» ÃËÁøÇÏ°í ÀÖÀ¸¸ç, ºñ¼Ò¼¼Æ÷Æó¾Ï Ä¡·áÁ¦´Â Á¾¾çÇп¡¼­ ºü¸£°Ô ¹ßÀüÇÏ°í ÀÖ´Â ºÐ¾ß·Î ºÎ»óÇÏ°í ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê(ÁÖ¸ñ 34°³»ç)

  • AstraZeneca
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene Corp.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genentech Inc.
  • GlaxoSmithKline plc
  • Novartis
  • Pfizer Inc.
  • Roche Holding AG
  • Sun Pharmaceutical Industries Ltd.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå °³¿ä
  • ÁÖ¿ä ±â¾÷
  • ½ÃÀå µ¿Çâ°ú ¼ºÀå ÃËÁø¿äÀÎ
  • ¼¼°è ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ºÐ¼®

  • ¹Ì±¹
  • ij³ª´Ù
  • ÀϺ»
  • Áß±¹
  • À¯·´
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • ÀÌÅ»¸®¾Æ
  • ¿µ±¹
  • ½ºÆäÀÎ
  • ·¯½Ã¾Æ
  • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • È£ÁÖ
  • Àεµ
  • Çѱ¹
  • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • ¾Æ¸£ÇîƼ³ª
  • ºê¶óÁú
  • ¸ß½ÃÄÚ
  • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿
  • À̶õ
  • À̽º¶ó¿¤
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®
  • ±âŸ Áßµ¿
  • ¾ÆÇÁ¸®Ä«

Á¦4Àå °æÀï

ksm 24.11.18

Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market to Reach US$54.0 Billion by 2030

The global market for Non-Small Cell Lung Cancer (NSCLC) Therapeutics estimated at US$30.4 Billion in the year 2023, is expected to reach US$54.0 Billion by 2030, growing at a CAGR of 8.5% over the analysis period 2023-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 9.6% CAGR and reach US$31.3 Billion by the end of the analysis period. Growth in the Immunotherapy segment is estimated at 7.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$7.9 Billion While China is Forecast to Grow at 12.9% CAGR

The Non-Small Cell Lung Cancer (NSCLC) Therapeutics market in the U.S. is estimated at US$7.9 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$14.1 Billion by the year 2030 trailing a CAGR of 12.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.2% and 7.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market - Key Trends and Drivers Summarized

Why Are Non-Small Cell Lung Cancer (NSCLC) Therapeutics Crucial in Oncology?

Non-Small Cell Lung Cancer (NSCLC) represents the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases globally. NSCLC therapeutics are designed to target specific genetic mutations, improve patient survival rates, and reduce the side effects associated with traditional chemotherapy. Treatment modalities include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy, with the latter two showing significant promise in improving outcomes for advanced-stage NSCLC. As the global burden of lung cancer continues to rise, NSCLC therapeutics have become a focal point in oncology, providing more personalized treatment options for patients.

What Are the Key Segments in the NSCLC Therapeutics Market?

Key treatment types include chemotherapy, targeted therapy, immunotherapy, and combination therapy, with targeted and immunotherapies experiencing rapid growth due to their effectiveness in specific genetic subtypes of NSCLC. In terms of drug class, the market includes EGFR inhibitors, ALK inhibitors, PD-1/PD-L1 inhibitors, and VEGF inhibitors, among others. Mutation-specific therapies, such as those targeting EGFR and ALK mutations, have been particularly successful in extending progression-free survival in patients. Major end-users include hospitals, cancer treatment centers, and research institutes, all of which are incorporating these advanced therapies into NSCLC management protocols.

How Are NSCLC Therapeutics Transforming Cancer Care?

Hospitals and oncology centers are integrating NSCLC therapeutics into personalized treatment plans, guided by genetic testing and biomarker analysis. Targeted therapies, such as EGFR inhibitors and ALK inhibitors, are often prescribed for patients with specific mutations, offering more effective treatment with fewer side effects compared to traditional chemotherapy. Immunotherapies, such as PD-1/PD-L1 inhibitors, are being used in both first-line and second-line settings, enhancing survival outcomes in advanced NSCLC cases. Research institutes and pharmaceutical companies are actively developing new drugs and conducting clinical trials to expand the range of effective treatments for NSCLC. Additionally, combination therapies that integrate targeted agents with immunotherapy are showing promising results in improving patient outcomes and managing resistance to single-drug treatments.

What Factors Are Driving the Growth in the NSCLC Therapeutics Market?

The growth in the NSCLC Therapeutics market is driven by several factors, including the increasing prevalence of lung cancer, which has intensified the demand for effective treatment options. Advances in genomics and personalized medicine have accelerated the development of targeted therapies, allowing for more precise treatment of specific NSCLC subtypes. The success of immunotherapy in improving survival rates has further propelled the adoption of innovative NSCLC drugs. Regulatory approvals and expanding research initiatives have also facilitated the entry of new therapeutics into the market. The growing awareness of genetic testing and biomarker identification has enhanced the adoption of targeted therapies, contributing to market growth. Additionally, government funding and investments in cancer research have supported the development of novel treatments, making NSCLC therapeutics a rapidly evolving field in oncology.

Select Competitors (Total 34 Featured) -

  • AstraZeneca
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene Corp.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genentech Inc.
  • GlaxoSmithKline plc
  • Novartis
  • Pfizer Inc.
  • Roche Holding AG
  • Sun Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Global Economic Update
    • Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Targeted and Immuno-Oncology Therapies Spurs Growth in NSCLC Therapeutics Market
    • Technological Advancements in Biomarker Discovery and Genomic Profiling Strengthen Business Case for Adoption
    • Growing Focus on Precision Medicine and Personalized Treatment Expands Addressable Market for NSCLC Therapeutics
    • Expansion of NSCLC Therapeutics in Hospitals, Cancer Centers, and Specialty Clinics Fuels Market Growth
    • Increasing Adoption of NSCLC Therapeutics in Adjuvant, Neoadjuvant, and Palliative Settings Expands Market Opportunities
    • Technological Innovations in Monoclonal Antibodies, PD-1/PD-L1 Inhibitors, and EGFR-TKIs Propel Market Expansion
    • Growing Use of Combination Therapies in Advanced and Metastatic NSCLC Expands Market Potential
    • Focus on Meeting Reimbursement Policies and Expanding Access to Novel NSCLC Drugs Strengthens Market for Therapeutics
    • Technological Advancements in Liquid Biopsy and ctDNA Analysis Propel Market Growth
    • Increasing Focus on Integrating NSCLC Therapies with Digital Health Platforms and Remote Monitoring Drives Adoption
    • Rising Demand for NSCLC Therapeutics in Immunotherapy and Chemotherapy-Resistant Cases Strengthens Global Market
    • Expansion of NSCLC Therapeutics in First-Line, Second-Line, and Maintenance Therapies Expands Market Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Adenocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Adenocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Adenocarcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Squamous Cell Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Squamous Cell Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Squamous Cell Carcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Large Cell Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Large Cell Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Large Cell Carcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • JAPAN
    • Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • CHINA
    • Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • EUROPE
    • Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • FRANCE
    • Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • GERMANY
    • Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • INDIA
    • Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • AFRICA
    • Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030

IV. COMPETITION

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦